{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:57:55Z","timestamp":1793829475962,"version":"4.6.1"},"reference-count":25,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual level data from a contemporary cohort of 6\u200929\u2009624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95%\u2009CI 74.0 to 76.4), 48.8% (40.9\u201356.8%) had ischaemic heart disease and 34.5% (29.4\u201339.6%) had diabetes. In 51\u2009442 patients with a recorded ejection fraction (EF), 39.1% (30.3\u201347.8%) had a reduced, 18.8% (13.5\u201324.0%) had a mildly reduced and 42.1% (31.5\u201352.8%) had a preserved left ventricular EF. In 1\u200969\u2009518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III\u2013V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We estimate that 1\u20132% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2022-321702","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T20:00:16Z","timestamp":1676318416000},"page":"548-556","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":69,"title":["Prevalence, outcomes and costs of a contemporary, multinational population with heart failure"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-0132","authenticated-orcid":false,"given":"Anna","family":"Norhammar","sequence":"first","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3967","authenticated-orcid":false,"given":"Johan","family":"Bodegard","sequence":"additional","affiliation":[{"name":"CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vanderheyden","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, OLV Hospital, Aalst, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Karasik","sequence":"additional","affiliation":[{"name":"Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Fondazione ReS Ricerca e Salute, Bologna, Italy"},{"name":"ANMCO Research Center, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne","family":"Sveen","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Oslo, Norway"},{"name":"University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Taveira-Gomes","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Decision in Health, University of Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Botana","sequence":"additional","affiliation":[{"name":"University Hospital Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hunziker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[{"name":"Statisticon, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-3411","authenticated-orcid":false,"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Institute of Health Informatics, University College London, London, UK"},{"name":"Department of Cardiology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-8454","authenticated-orcid":false,"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"The George Institute for Global Health, Newtown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bollmann","sequence":"additional","affiliation":[{"name":"Heart Center Leipzig, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"2025092001543349000_109.7.548.1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"03","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2025092001543349000_109.7.548.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(01)00198-2"},{"key":"2025092001543349000_109.7.548.3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025092001543349000_109.7.548.4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025092001543349000_109.7.548.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2025092001543349000_109.7.548.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2025092001543349000_109.7.548.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2025092001543349000_109.7.548.8","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"2022","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2025092001543349000_109.7.548.9","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"Esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2021","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092001543349000_109.7.548.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"2025092001543349000_109.7.548.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32520-5"},{"key":"2025092001543349000_109.7.548.12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025092001543349000_109.7.548.13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025092001543349000_109.7.548.14","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","article-title":"Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the CaReMe CKD study","volume":"20","author":"Sundstr\u00f6m","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025092001543349000_109.7.548.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.12.007"},{"key":"2025092001543349000_109.7.548.16","doi-asserted-by":"crossref","unstructured":"Rosano GMC , Seferovic P , Savarese G , et al . Impact analysis of heart failure across European countries: an ESC\u2010HFA position paper. ESC Heart Fail;26.doi:10.1002\/ehf2.14076","DOI":"10.1002\/ehf2.14076"},{"key":"2025092001543349000_109.7.548.17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/CLEP.S170873","article-title":"Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden","volume":"11","author":"Lindmark","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2025092001543349000_109.7.548.18","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025092001543349000_109.7.548.19","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2025092001543349000_109.7.548.20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.813"},{"key":"2025092001543349000_109.7.548.21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2020.04.068","article-title":"Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design","volume":"313","author":"Savarese","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025092001543349000_109.7.548.22","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025092001543349000_109.7.548.23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025092001543349000_109.7.548.24","doi-asserted-by":"crossref","unstructured":"Savarese G , Kishi T , Vardeny O , et al . Heart failure drug Treatment-Inertia, titration, and discontinuation: a multinational observational study (evolution HF). JACC Heart Fail 2022.doi:10.1016\/j.jchf.2022.08.009","DOI":"10.1016\/j.jchf.2022.08.009"},{"key":"2025092001543349000_109.7.548.25","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1093\/eurheartj\/ehab360","article-title":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Lam","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T08:54:40Z","timestamp":1758358480000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/heartjnl-2022-321702"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321702","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}